184 related articles for article (PubMed ID: 29755112)
1. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma.
Lohneis P; Sinn M; Klein F; Bischoff S; Striefler JK; Wislocka L; Sinn BV; Pelzer U; Oettle H; Riess H; Denkert C; Bläker H; Jühling A
Br J Cancer; 2018 May; 118(11):1485-1491. PubMed ID: 29755112
[TBL] [Abstract][Full Text] [Related]
2. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
3. Tumour budding is a strong and independent prognostic factor in pancreatic cancer.
Karamitopoulou E; Zlobec I; Born D; Kondi-Pafiti A; Lykoudis P; Mellou A; Gennatas K; Gloor B; Lugli A
Eur J Cancer; 2013 Mar; 49(5):1032-9. PubMed ID: 23177090
[TBL] [Abstract][Full Text] [Related]
4. Tumor budding as a prognostic factor in pancreatic ductal adenocarcinoma.
Petrova E; Zielinski V; Bolm L; Schreiber C; Knief J; Thorns C; Bronsert P; Timme-Bronsert S; Bausch D; Perner S; Keck T; Wellner U
Virchows Arch; 2020 Apr; 476(4):561-568. PubMed ID: 31786688
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma.
Pergolini I; Crippa S; Pagnanelli M; Belfiori G; Pucci A; Partelli S; Rubini C; Castelli P; Zamboni G; Falconi M
BJS Open; 2019 Oct; 3(5):646-655. PubMed ID: 31592095
[TBL] [Abstract][Full Text] [Related]
7. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
8. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.
John BJ; Naik P; Ironside A; Davidson BR; Fusai G; Gillmore R; Watkins J; Rahman SH
HPB (Oxford); 2013 Sep; 15(9):674-80. PubMed ID: 23458477
[TBL] [Abstract][Full Text] [Related]
9. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
10. The role of coeliac axis resection in resected ductal adenocarcinoma of the distal pancreas: A result of tumour topography or a prognostic factor?
Liu B; Wu J; Li C; Li Y; Qiu H; Lv A; Liu Q; Liu D; Wang Z; Hao C
Pancreatology; 2022 Jan; 22(1):112-122. PubMed ID: 34764022
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Lohneis P; Sinn M; Bischoff S; Jühling A; Pelzer U; Wislocka L; Bahra M; Sinn BV; Denkert C; Oettle H; Bläker H; Riess H; Jöhrens K; Striefler JK
Eur J Cancer; 2017 Sep; 83():290-301. PubMed ID: 28772128
[TBL] [Abstract][Full Text] [Related]
12. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive histological evaluation with clinical analysis of venous invasion in pancreatic ductal adenocarcinoma: From histology to clinical implications.
Lee SJ; Sung YN; Kim SJ; Shin S; Cho H; Hruban RH; Hong SM
Pancreatology; 2020 Oct; 20(7):1486-1494. PubMed ID: 32948429
[TBL] [Abstract][Full Text] [Related]
14. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
16. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
17. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
O'Connor K; Li-Chang HH; Kalloger SE; Peixoto RD; Webber DL; Owen DA; Driman DK; Kirsch R; Serra S; Scudamore CH; Renouf DJ; Schaeffer DF
Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
[TBL] [Abstract][Full Text] [Related]
18. Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma.
Lohneis P; Hieggelke L; Gebauer F; Ball M; Bruns C; Büttner R; Löser H; Quaas A
Virchows Arch; 2021 Mar; 478(3):393-400. PubMed ID: 32761393
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
20. Does Size Matter in Pancreatic Cancer?: Reappraisal of Tumour Dimension as a Predictor of Outcome Beyond the TNM.
Marchegiani G; Andrianello S; Malleo G; De Gregorio L; Scarpa A; Mino-Kenudson M; Maggino L; Ferrone CR; Lillemoe KD; Bassi C; Castillo CF; Salvia R
Ann Surg; 2017 Jul; 266(1):142-148. PubMed ID: 27322188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
